Adverse events from targeted therapies in advanced renal cell carcinoma: The impact on long-term use

BJU International

Volumn 107, Issue 11, 2011, Pages 1722-1732

  Kirkali, Ziya ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

adverse events; renal cell carcinoma; targeted therapies

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; EVEROLIMUS; INSULIN; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTERY THROMBOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRY SKIN; DYSGEUSIA; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMOLYTIC UREMIC SYNDROME; HEPATOBILIARY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPERTENSIVE CRISIS; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INFECTION; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY SURGERY; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LYMPHOCELE; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEUTROPENIA; PANCREAS DISEASE; PATIENT COUNSELING; PATIENT EDUCATION; PERICARDIAL EFFUSION; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; QT PROLONGATION; RASH; SEPSIS; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MOLECULAR TARGETED THERAPY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79956368946     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09985.x     Document Type: Article

References (53)

1. EU SmPC Nexavar: November: 2009. Available at:. Accessed 10 November 2010
2. EU SmPC Sutent: August: 2009. Available at:. Accessed 10 November 2010
3. Escudier B, Eisen T, Stadler WM, et al,. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-8
4. Stadler WM, Figlin RA, McDermott DF, et al,. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116: 1272-80
5. Hutson TE, Bellmunt J, Porta C, et al,. Long-term safety with sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010; 46: 2432-40
6. Motzer RJ, Hutson TE, Tomczak P, et al,. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90
7. Gore ME, Szczylik C, Porta C, et al,. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63
8. Porta C, Szczylik C, Bracarda S, et al,. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008; 26: abstract 5114
9. EU SmPC Avastin: April: 2009. Available at:. Accessed 10 November 2010
10. EU SmPC Torisel: May: 2009. Available at:. Accessed 10 November 2010
11. EU SmPC Afinitor: August: 2009. Available at:. Accessed 10 November 2010
12. US PI Votrient FDA: October: 2009. Available at:. Accessed 10 November 2010
13. Beck J, Procopio G, Negrier S, et al,. Final analysis of a large open-label, noncomparative, phase 3 study of sorafenib in European patients with advanced RCC (EU-ARCCS). Eur J Cancer Suppl 2009; 7: 434-5, abstract P-7137
14. Escudier B, Pluzanska A, Koralewski P, et al,. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11 (Pubitemid 350296300)
15. Hudes G, Carducci M, Tomczak P, et al,. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81 (Pubitemid 46849157)
16. Kay A, Motzer RJ, Figlin RA, et al,. Updated data from a phase III trial of everolimus (RAD001) versus placebo in patients with metastatic renal cell carcinoma. Eur Urol Suppl 2009; 8: 185; abstract 257
17. Zimmermann K, Schmittel A, Steiner U, et al,. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009; 76: 350-4
18. Sternberg CN, Davis ID, Mardiak J, et al,. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8
19. Wolter P, Wildiers H, Vanderschueren D, Dumez H, Clement P, Schöffski P,. Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR). J Clin Oncol 2009; 27; abstract 3565
20. National Comprehensive Cancer network. NCCN clinical practice guidelines in oncology: cancer-related fatigue. Available at:. Accessed February 2010
21. Esper P, Gale D, Muehlbauer P,. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies. Clin J Oncol Nurs 2007; 11: 659-66
22. Lee WJ, Lee JL, Chang SE, et al,. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-51
23. Autier J, Escudier B, Wechsler J, Spatz A, Robert C,. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144: 886-92 (Pubitemid 352039741)
24. Porta C, Paglino C, Imarisio I, Bonomi L,. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007; 7: 127-34
25. Riogas J,. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Eur Urol Suppl 2008; 7: 593-600
26. Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME,. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14: 291-302
27. Bhojani N, Jeldres C, Patard JJ, et al,. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917-30
28. Negrier S, Ravaud A,. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl 2007; 5: 12-9 (Pubitemid 350017071)
29. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B,. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60: 299-305
30. Wood L,. Managing the side effects of sorafenib and sunitinib. Community Oncol 2006; 3: 558-62 (Pubitemid 44785334)
31. Dasanu CA, Alexandrescu DT, Dutcher J,. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J 2007; 100: 328-30 (Pubitemid 46673440)
32. Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M,. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009; 69: 64-72
33. O'Brien BE, Kaklamani VG, Benson AB 3rd,. The assessment and management of cancer treatment-related diarrhoea. Clin Colorectal Cancer 2005; 4: 375-81 (Pubitemid 41268773)
34. Benson AB 3rd, Ajani JA, Catalano RB, et al,. Recommended guidelines for the treatment of cancer treatment-induced diarrhoea. J Clin Oncol 2004; 22: 2918-26 (Pubitemid 41079912)
35. Bamias A, Lainakis G, Manios E, et al,. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother 2009; 21: 347-50
36. Mancia G, De Backer G, Dominiczak A, et al,. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87 (Pubitemid 46924065)
37. Finnish Medical Society Duodecim. Thrombocytopenia. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland. Wiley Interscience. John Wiley & Sons; 2007. Available at:. Accessed 10 November 2010
38. Motzer RJ, Escudier B, Oudard S, et al,. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56
39. Ossa D, Briggs A, McIntosh E, Cowell W, Littlewood T, Sculpher MJ,. Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics 2007; 25: 223-37 (Pubitemid 46376832)
40. Porta C, Szczylik C,. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009; 35: 297-307
41. Thibault F, Billemont B, Richard F, Rixe O,. Perioperative use and surgical complications of sunitinib in metastatic renal cell carcinoma. J Urol 2008; 179 (Suppl.): 169
42. Tamaskar I, Bukowski R, Elson P,. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008; 19: 265-8 (Pubitemid 351201706)
43. AACE Thyroid Task Force. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2006; 8: 457-69
44. Rini BI, Halabi S, Rosenberg JE, et al,. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8
45. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP,. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; 115: 2438-46
46. Albiges L, Caramella C, Dromain C, et al,. Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis. Eur J Cancer Suppl 2009; 7: 427, abstract PD-7114
47. Pablo M, Hudes G, Dutcher J, et al,. Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus. Eur J Cancer Suppl 2009; 7: 426-7, abstract PD-7113
48. White DA, Camus P, Endo M, et al,. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403
49. Tolcher A, Appleman L, Mita A, et al,. Effect of sorafenib treatment on left ventricular ejection fraction and other cardiovascular safety parameters in cancer patients: an open-label, phase I study. Ann Oncol 2008; 19 (Suppl. 8): viii179, abstract 552P
50. Je Y, Schutz FA, Choueiri TK,. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10: 967-74
51. Motzer RJ, Hutson TE, Tomczak P, et al,. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24 (Pubitemid 46089672)
52. Eichelberg C, Heuer R, Chun FK, et al,. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008; 54: 1373-8
53. Rini BI, Hutson TE, Elson P, et al,. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. ASCO Genitourinary Cancer Symposium 2010; abstract 319